key: cord-0724325-6xbpy4jp
authors: Aparisi, Álvaro; Catalá, Pablo; Amat-Santos, Ignacio J; Marcos, Marta; López-Otero, Diego; Veras, Carlos; López-Pais, Javier; Cabezón, Gonzalo; Antonio, Carla Eugenia Cacho; Candela, Jordi; Antúnez-Muiños, Pablo; Francisco-Gil, José; Ferrero, Teba González; Rojas, Gino; Pérez-Poza, Marta; Uribarri, Aitor; Otero-García, Oscar; García-Granja, Pablo Elpidio; Ramos, Víctor Jiménez; Revilla, Ana; Dueñas, Carlos; Gómez, Itzíar; Ramón González-Juanatey, José; Alberto San Román, J
title: Chronic Use Of Renin-Angiotensin-Aldosterone Inhibitors In Hypertensive Covid-19 Patients: Results From A Spanish Registry And Meta-Analysis
date: 2021-05-06
journal: Med Clin (Barc)
DOI: 10.1016/j.medcli.2021.04.005
sha: 276975951522ebc4ab6a83f0e674d28870de9c54
doc_id: 724325
cord_uid: 6xbpy4jp

Background: Hypertension is a prevalent condition among SARS-CoV-2 infected patients. Whether renin-angiotensin-aldosterone system (RAAS) inhibitors are beneficial or harmful is controversial. Methods: We have performed a national retrospective, nonexperimental comparative study from two tertiary hospitals to evaluate the impact of chronic use of RAAS inhibitors in hypertensive COVID-19 patients. A meta-analysis was performed to strengthen our findings. Results: Of 849 patients, 422 (49.7%) patients were hypertensive and 310 (73.5%) were taking RAAS inhibitors at baseline. Hypertensive patients were older, had more comorbidities, and a greater incidence of respiratory failure (-0.151 [95% CI -0.218, -0.084]). Overall mortality in hypertensive patients was 28.4%, but smaller among those with prescribed RAAS inhibitors before (-0.167 [95% CI -0.220, -0.114]) and during hospitalization (0.090 [-0.008,0.188]). Similar findings were observed after two propensity score matches that evaluated the benefit of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers among hypertensive patients. Multivariate logistic regression analysis of hypertensive patients found that age, diabetes mellitus, C-reactive protein, and renal failure were independently associated with all-cause mortality. On the contrary, ACEIs decreased the risk of death (OR 0.444 [95% CI 0.224-0.881]). Meta-analysis suggested a protective benefit of RAAS inhibitors (OR 0.6 [95% CI 0.42-0.8]) among hypertensive COVID-19. Conclusion: Our data suggest that RAAS inhibitors may play a protective role in hypertensive COVID-19 patients. This finding was supported by a meta-analysis of the current evidence. Maintaining these medications during hospital stay may not negatively affect COVID-19 outcomes.

. Se observaron hallazgos similares tras dos emparejamientos de puntuación de propensión que evaluaron el beneficio de los inhibidores de la enzima convertidora de angiotensina y los bloqueadores de los receptores de angiotensina entre los pacientes hipertensos. El análisis de regresión logística multivariante de los pacientes hipertensos reveló que la edad, la diabetes mellitus, la proteína C reactiva y la insuficiencia renal se asociaban de forma independiente con la mortalidad por todas las causas. Por el contrario, los IECAs disminuyeron el riesgo de muerte (OR 0,444 [IC del 95%: 0,224-0,881]). El meta-análisis sugirió un beneficio protector de los inhibidores del SRAA (OR 0,6 [IC del 95%: 0,42-0,8]) entre los hipertensos con COVID-

Conclusión: Nuestros datos sugieren que los inhibidores del SRAA pueden desempeñar un papel protector en los pacientes hipertensos COVID-19. Este hallazgo fue apoyado por un meta-análisis de la evidencia actual. Su mantenimiento durante la estancia hospitalaria puede no afectar negativamente a los resultados de la COVID-19.

In early December of 2019, several patients from Wuhan were found to have viral pneumonia caused by the acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Nobody could imagine then that this could lead to the coronavirus disease 2019 (COVID-19) outbreak with an estimated global mortality of 2.3% after 61,299,371 infected people worldwide 1 .

The virus enters the cell by binding its trimeric spike protein to the human receptor angiotensin-converting enzyme 2 (ACE2) and the activity of the serine protease TMPRSS2 for S protein priming. 2, 3 Expression of ACE2 is upregulated in cardiovascular disease, 4 and in patients with diabetes mellitus and hypertension, 5 which may favor the entrance of the SARS-CoV-2 into the cells and increase the virulence of the virus in the lung and heart. Moreover, renin-angiotensinaldosterone system (RAAS) blockade increases the expression and activity of cardiac ACE2. 6 On the other hand, recombinant human ACE2 has been shown to protect the ACE2-deficient mice model from lung failure in SARS induced by acid aspiration, 7 and have been seen in severe cases of COVID- 19. 8 Importantly, angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin-receptor blockers (ARBs) block the RAAS by means of different mechanisms, so that their effects on ACE2 expression and activity should be different as well. Therefore, some authors warn about the harmful effect of RAAS blockers and advise its discontinuation to prevent poor outcome 9 while others claim to maintain these drugs until more evidence was available. 10 The aim of this national multicenter retrospective study was to 1) evaluate the impact of chronic RAAS inhibitors in hypertensive patients with COVID-19 and 2) estimate its average effect through a meta-analysis of the current evidence.

This is a retrospective nonexperimental comparative study from two tertiary Spanish centers (Hospital Clínico Universitario de Valladolid; Hospital Clínico Universitario de Santiago de Compostela) to evaluate the impact of chronic use of RAAS inhibitors in hypertensive COVID- The study was approved by our local ethics committee and consent was waived due to the retrospective nature of the study. Following the approval, a retrospective analysis of all the COVID-19 patients was performed dividing them into two groups according to their prior history of hypertension. Hypertensive patients were further classified according to their medical therapy before hospital admission into two groups: 1) renin-angiotensin-aldosterone system (RAAS) inhibitors and 2) those without RAAS inhibitors (see supplementary material, Figure-1 ). A total of 422 patients were included in the final analysis. The procedural strategy was established according to the protocols of each participating institution; however, the decision to maintain or withdraw RAAS inhibitors was determined according to the criteria of the treating medical team.

The primary end-point was to evaluate all-cause mortality in hypertensive patients with and without RAAS inhibitors. Secondary outcomes were to assess the incidence of respiratory failure and any difference between ACEIs vs. ARB inhibitors.

Fever was considered when the temperature was over >37.5 o C. Respiratory failure was defined as paO2 < 60 mmHg, O2 saturation measured with pulse oximetry of < 92% breathing room air, and need for invasive or non-invasive mechanical ventilation. Chronic renal failure was defined as a glomerular filtration rate < 60 ml/min or need for dialysis.

Categorical variables are reported as absolute values and percentages. Continuous variables are reported as the mean ± standard deviation or median and interquartile range. The normal distribution of quantitative variables was verified with the Kolmogorov-Smirnov test. Differences and their 95% confidence interval were calculated for all comparisons and considered significantly if 0 was not within the interval.

To identify factors that were predictive of death, a logistic regression model with the maximum likelihood method was constructed by using backward stepwise selection, which included the variables that were statistically significant in the bivariate analysis or clinically relevant. No more than 1 variable per 10 outcome events was entered in the logistic model to avoid overfitting. For the final model, we calculated odds ratios (OR) adjusted for each of the variables included, along with their 95% confidence interval (CI). Goodness of fit for each model was determined with the Hosmer-Lemeshow test and area under the curve.

To evaluate the impact of ACE and ARB inhibitors to find out whether COVID-19 hypertensive patients may benefit from an increased survival, a propensity score analysis was performed. The dependent variable was either ACEIs or ARBs and the independent variables chosen were: age, diabetes mellitus, chronic kidney disease, chronic obstructive pulmonary disease, ischemic heart disease, creatinine>1.5 mg/dl and the hospital to match patients from the same center to inhibit potential differences in medical practices. Importantly, in the propensity analysis performed to test the benefit of ACEIs, patients taking ARBs were excluded from the matched cohort In the meta-analysis, as a measure of the combined effect for the included studies, the OR was estimated, their 95 CI% and its statistical significance. The homogeneity between studies was contrasted by the QH statistic. Concerning the low sensitivity of this test, we consider p <0.10 values as significant. To overcome this limitation in some way, the I2 statistic was estimated as well, which measures the proportion of the total variation of the studies explained by the heterogeneity and its 95% CI. A random-effects model was used for those cases in which the I2 statistic was greater than 50% and a model of fixed effects for the opposite cases. 

Main baseline characteristics and outcomes are summarized in Table- 

The main characteristics of hypertensive patients are summarized in Table- We performed a PSM to further evaluate the benefit of RAAS inhibitors, specifically whether chronic ACEIs or ARBs still show an association with lower all-cause mortality among hypertensive COVID-19 patients (see Table 3 ) after adjustment for potential cofounders.

Compared with non-RAAS inhibitors, the incidence of all-cause mortality was lower irrespective of ACEIs (-0.136 [95% CI -0.279, -0.047]) or ARBs (-0.130 [95% CI -0.297, -0.039]) users in comparison to non-users. To further explore their potential benefit during in-hospital use, despite the small sample, we observed in the matched cohort that continuation of RAAS inhibitors were not associated with greater mortality the least

After a univariate analysis of the hypertensive COVID-19 patients, a logistic regression model was performed (see Table 4 ) including the following variables: age, diabetes mellitus, chronic kidney disease, ischemic heart disease, ACEIs at admission, ARBs at admission, lym-phocytes<1,000/mm 3 , lactate dehydrogenase >250 U/l, D-dimer >500 microgram/l, creati-nine>1.5 mg/dl, C-reactive protein>10 mg/l and hospital. The final model identified that among hypertensive patients age, diabetes mellitus, C-reactive protein, and creatinine were associated with a greater risk of all-cause mortality. On the contrary, ACEIs at admission independently Table S1 ) [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] . Exclusion criteria were: 1) non-peer-reviewed papers from preprint servers, 2) abstracts, and 3) samples < 100 patients. The following terms were searched: "COVID-19" or "SARS-CoV-2" and "hypertension" and "renin-angiotensin-aldosterone system" or "angiotensin receptor blocker" or "angiotensin-converting enzyme inhibitor". The study quality of the selected was assessed by using Newcastle-Ottawa Scale (NOS ; Table S1 ). Overall, prior use of RAAS inhibitors among admitted hypertensive COVID-19 patients was associated with lower all-cause mortality (OR 0.6 [95% CI 0.42-0.8]; p<0.003) (Figure 1-A) . We did not observe a protective effect of RAAS inhibitors in respect to mechanical ventilation (OR 2.12 [95% CI 0.66-6.80]; p= 0.21) (Figure 1-B) or intensive care unit admission (OR 0.84 [95% CI 0.41-1.72]; p= 0.63) (Figure 1-C) .

Ever since the beginning of the current global outbreak, the potential beneficial or harmful effects of RAAS inhibitors have been a subject of ongoing discussions. Our main findings are: 1) in hypertensive COVID-19 patients prior treatment with RAAS inhibitors were associated with a lower risk of all-cause mortality; 2) this protective benefit was also observed after PSM in both Interestingly, two retrospective studies showed a neutral effect on mortality of previous treatment with RAAS inhibitors 27, 28 , these differences could be explained by the fact that they evaluate a low-risk population. On the contrary, high-risk COVID-19 patients are characterized by heart disease 29 and a great burden of several cardiovascular risk factors; In particular, hypertension is associated with disease severity and mortality 30, SR1 .

We have observed in our cohort a high prevalence of hypertensive patients (49.7%), of whom 73.5% were under chronic RAAS treatment. ACE2 favors SARS-CoV-2 entry into the cells SR2 , RAAS inhibitors have shown in experimental models to increase ACE2 expression 6, SR3, SR4 and AG-II plasma levels were correlated with total viral load and severity of lung injury in COVID-19 patients SR5 . An interesting clinical study performed on 1,128 patients suggests that RAAS blockade is beneficial in the context of previous hypertension and COVID -19 29 . Nevertheless, the inclusion criteria were very stringent: only patients who received RAAS blockade during hospital stay were considered so that nothing is known about patients who were on those medications before admission, and only 31 patients took ACE inhibitors. More importantly, patients older than 74 years have been excluded from the study; older patients are particularly affected by COVID-19, with 35,5% older than 74 years in our series, and bear poor prognosis.

Taken into account this information, we decided to explore the impact of chronic use of RAAS inhibitors in hypertensive COVID-19 separately.

Our work suggests that maintenance RAAS blockade exceeds by far the negative effects shown in experimental studies. According to our findings, hypertensive patients from our sample had higher crude mortality in comparison to non-hypertensive patients, but an adjusted regression logistic analysis and both propensity score analysis showed a positive association between previous treatment with RAAS inhibitors in hypertensive COVID-19 patients. Our results support the well-known protective effects of blocking the RAAS in hypertension, diabetes mellitus, chronic kidney disease, and ischemic heart disease that may offset any putative assistance to the SARS-CoV-2 entrance into the cells.

To further address the impact of chronic use of RAAS inhibitors in hypertensive COVID-19 patients, we performed a meta-analysis [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] . In this meta-analysis, previous treatment with RAAS inhibitors was associated with a lower risk of all-cause mortality among hospitalized hypertensive COVID-19 patients. Moreover, we found a neutral effect on intensive care unit admission and the need of mechanical ventilation. Several are the potential explanations, particularly if we take into account the high observed heterogenicity, but a meta-regression analysis ruled out a potential contributing role of the studied sample seized. Thereby, other major explanations could be a "healthy user-sick stopper" SR6 or delayed hospitalization among other unmeasured cofounders.

Overall, additional studies are still needed to elucidate all the potential scenarios as many studies have not been designed to detect a potential causal association or identify differences between ACEi and ARB. In this sense, some studies are testing whether losartan improves outcomes in COVID-19. Previous studies and our findings suggest that RAAS blockade is not harmful before and during the hospital stay in hypertensive patients, but the majority of ongoing trials include patients without chronic RAAS blockers intake who have respiratory failure (NCT J o u r n a l P r e -p r o o f 04312009, NCT 04340557, NCT 04335123), a completely different scenario. Based on the current evidence, losartan could be of benefit in ambulatory COVID-19 patients as it is being tested in another trial (NCT 04311177) although that is again a different subset of patients. In this regard, the investigators of the RASTAVI trial (NCT03201185), which is currently randomizing patients with severe aortic stenosis who have an indication for a percutaneous aortic prosthesis to ramipril or not, showed that randomization to ramipril had no impact on the incidence or severity of COVID-19 SR7 .

The retrospective nature of our work bears the inherent limitations of this kind of investigation and should be considered as a hypothesis generator. First, the collection of data relies on documents not always updated; data on the specific drug and dosage have been checked when possible and always with the electronic records. Second, the results may not be generalizable as we did not evaluate outpatients and the meta-analysis should be interpreted cautiously due to the high heterogenicity, likely explained by the variability of the studied samples and especially with the disease severity or other unmeasured confounding factors (such as drug doses, time of inclusion, study design, etc.). The comparison between patients who maintain and discontinue RAAS blockers during hospital stay is biased since it can be assumed that these medications are halted in those who need mechanical ventilation or are in a worse clinical condition ("indication bias").

We cannot be certain of the impact of maintaining or withdrawing RAAS inhibitors in them.

To summarize, our results suggest a positive association between ACEIs and ARBs intake and survival in COVID-19 patients with preexisting hypertension who need hospitalization. Our findings are supported by a meta-analysis. Moreover, maintaining these medications during hospital stays may be associated with better outcomes. Future studies are warranted, as only a prospective randomized study in hypertensive patients free of the infection testing RAAS blockade against placebo would give us evidence-based answers.

Page 13 of 29 J o u r n a l P r e -p r o o f This work has received financial support from the Gerencia Regional de Salud de Castilla and León (GRS COVID 113/A/20).

The authors declare that they have no conflicts of interest 3 (-14.1, -10 Values are median (IQR), mean ± SD or n (%). Bold indicates significative differences . 

WHO. Coronavirus disease 2019 (COVID-19) situation report

Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Is There an Association Between COVID-19 Mortality and the Renin-Angiotensin System-a Call for Epidemiologic Investigations

Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?

Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2

Angiotensin-converting enzyme 2 protects from severe acute lung failure

Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury

Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic?

Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19

Angiotensin converting enzyme inhibitors and angiotensin receptor blockers improved the Page 18 of 29 patients with severe COVID-19 and hypertension

Mortality and Prehospitalization use of Renin-Angiotensin system inhibitors in Hypertensive COVID-19 patients

Clinical Features of COVID-19 in Patients With Essential Hypertension and the Impacts of Renin-angiotensinaldosterone System Inhibitors on the Prognosis of COVID-19 Patients

Effects of Angiotensin II Receptor Blockers and ACE (Angiotensin-Converting Enzyme) Inhibitors on Virus Infection, Inflammatory Status, and Clinical Outcomes in Patients With COVID-19 and Hypertension: A Single-Center Retrospective Study

Use of RAAS Inhibitors and Risk of Clinical Deterioration in COVID-19: Results From an Italian Cohort of 133 Hypertensives

Antecedent Administration of Angiotensin-Converting Enzyme Inhibitors or COVID-19 Syndrome

Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study

Impact of Treatment with Renin-Angiotensin System Inhibitors on Clinical Outcomes in Hypertensive Patients Hospitalized with COVID-19

Use of angiotensinconverting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis

Continued In-Hospital Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker Use in Hypertensive COVID-19 Patients Is Associated With Positive Clinical Outcome

Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China

Enzyme Inhibitors Or Angiotensin II Receptor Blockers And Prognosis Of Hypertensive Patients Hospitalized With COVID-19

COVID-19 is more severe in patients with hypertension

ACEI/ARB treatment does not influence clinical severity and outcome

Is the use of ACE inb/ARBs associated with higher in-hospital mortality in Covid-19 pneumonia patients?

Estimation of Renin-Angiotensin-Aldosterone-System (RAAS)-Inhibitor effect on COVID-19 outcome: A Meta-analysis

Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19

Impact of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on COVID-19 in a western population. CARDIOVID registry

) 99 (-30,42) Lymphocytes (cells/mm³) 920